Author name: Kristen Hartman

Regulation of nociception threshold by norepinephrine through adrenergic α2 receptor in rat models of Parkinson’s disease

Gao Q, Zhang Y, Wang X, Wang R, Zhang L (2024) Regulation of nociception threshold by norepinephrine through adrenergic α2 receptor in rat models of Parkinson’s disease. CNS Neurosci Ther 30(3):e14446. doi: 10.1111/cns.14446 PMID: 37721421 Objective: To investigate the effect of norepinephrine on the activation of brain cells through adrenergic α2 receptor, to regulate the […]

Regulation of nociception threshold by norepinephrine through adrenergic α2 receptor in rat models of Parkinson’s disease Read More »

Exploring the potential of nanogels: From drug carriers to radiopharmaceutical agents

Kubeil M, Suzuki Y, Casulli MA, Kamal R, Hashimoto T, Bachmann M, Hayashita T, Stephan H (2023) Exploring the potential of nanogels: From drug carriers to radiopharmaceutical agents. Adv Healthc Mater e2301404. doi: 10.1002/adhm.202301404 PMID: 37717209 Summary: This review provides a brief overview of current developments of nanogels in the fields of drug delivery, therapeutic

Exploring the potential of nanogels: From drug carriers to radiopharmaceutical agents Read More »

Validated Antibodies: NGFR & Melanopsin

Targeting Topics /

Validated Antibodies targeting NGFR and Melanopsin NGFR Antibodies NGFR (mu p75) Rabbit Polyclonal [AB-N01] AB-N01 also known as mu p75, and the affinity-purified version, AB-N01AP recognize the p75 receptor in mouse. Applications include immunohistochemistry, immunoprecipitation, immunoblotting, flow cytometry, and blocking the function of nerve growth factor receptor. NGFR (ME20.4, p75) Mouse Monoclonal [AB-N07] AB-N07 also known

Validated Antibodies: NGFR & Melanopsin Read More »

Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review)

Thongchot S, Aksonnam K, Thuwajit P, Yenchitsomanus PT, Thuwajit C (2023) Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review). Int J Mol Med 52(3):81. doi: 10.3892/ijmm.2023.5284 PMID: 37477132 Objective: The authors review the mechanisms through which the multiple functions of NCL can participate in the progression of cancer. In addition, the studies

Nucleolin‑based targeting strategies in cancer treatment: Focus on cancer immunotherapy (Review) Read More »

pHast Conjugate Videos

Video /

pHast Conjugate Videos An introduction to our pHast product line: pH-sensitive fluorescent secondary conjugates designed to fluoresce when exposed to the environment inside of a cell. Also available in Chinese | French | German | Italian | Japanese | Korean | Portuguese | Spanish Also available in Chinese | French | German | Italian |

pHast Conjugate Videos Read More »

Screening targeting agents and their cell surface biomarkers for high specificity and rapid internalization via cell death and fluorescence.

Targeting Topics /

Screening targeting agents and their cell surface biomarkers for high specificity and rapid internalization via cell death and fluorescence. Ancheta L, Bouajram R, Lappi DA (2018) Society for Neuroscience, San Diego, CA. Abstract Some of the most recent successes in the treatment of cancers or research into passive immunotherapies for neurodegenerative diseases, employ the use

Screening targeting agents and their cell surface biomarkers for high specificity and rapid internalization via cell death and fluorescence. Read More »

PTGFRN as a target for antibody-drug conjugate (ADC) development in mesothelioma and medulloblastoma

Marquez J (2023) PTGFRN as a target for antibody-drug conjugate (ADC) development in mesothelioma and medulloblastoma. Univ Maryland Baltimore Thesis. Objective: To investigate the role of Prostaglandin F2 Receptor Negative (PTGFRN) regulator in cancer progression and develop an antibody-drug conjugate (ADC) targeting PTGFRN for the treatment of mesothelioma and pediatric medulloblastoma. Summary: This dissertation explores

PTGFRN as a target for antibody-drug conjugate (ADC) development in mesothelioma and medulloblastoma Read More »

Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases

Metz M, Kolkhir P, Altrichter S, Siebenhaar F, Levi-Schaffer F, Youngblood BA, Church MK, Maurer M (2023) Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases. Allergy doi: 10.1111/all.15850 PMID: 37605867 Objective: Authors review the role of mast cells (MC) in the pathogenesis of chronic urticaria (CU), explore current therapeutic

Mast cell silencing: A novel therapeutic approach for urticaria and other mast cell-mediated diseases Read More »

The induction of long-term potentiation by medial septum activation under urethane anesthesia can alter gene expression in the hippocampus

Dobryakova YV, Gerasimov K, Spivak YS, Korotkova T, Koryagina A, Deryabina A, Markevich VA, Bolshakov AP (2023) The induction of long-term potentiation by medial septum activation under urethane anesthesia can alter gene expression in the hippocampus. Int J Mol Sci 24(16):12970. doi: 10.3390/ijms241612970 PMID: 37629149 Objective: To study changes in the expression of early genes

The induction of long-term potentiation by medial septum activation under urethane anesthesia can alter gene expression in the hippocampus Read More »

The induction of long-term potentiation by medial septum activation under urethane anesthesia can alter gene expression in the hippocampus

Dobryakova YV, Gerasimov K, Spivak YS, Korotkova T, Koryagina A, Deryabina A, Markevich VA, Bolshakov AP (2023) The induction of long-term potentiation by medial septum activation under urethane anesthesia can alter gene expression in the hippocampus. Int J Mol Sci 24(16):12970. doi: 10.3390/ijms241612970 PMID: 37629149 Objective: To study changes in the expression of early genes

The induction of long-term potentiation by medial septum activation under urethane anesthesia can alter gene expression in the hippocampus Read More »

Search
Shopping Cart
Scroll to Top